The role of progesterone in maternal and fetal medicine

References

• Di Renzo GC, Mattei A, Gojnic M, Gerli S. Progesterone and pregnancy. Curr Opin Obstet Gynecol 2005;17:598–600.
   PubMed Web of Science ®Google Scholar
• Nahoul K, Dehennin L, Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem 1987;26:241–249.
   PubMedGoogle Scholar
• Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 1998;217:369–378.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril 1999;72:389–397.
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Rosati A, Mattei A, Gojnic M, Gerli S. The changing role of progesterone in preterm labour. BJOG 2005;112 Suppl 1:57–60.
   PubMed Web of Science ®Google Scholar
• Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, Franceschetti F. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073–1079.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403–406.
   PubMed Web of Science ®Google Scholar
• Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009;200:219–224.
   PubMed Web of Science ®Google Scholar
• Kurjak A, Chervenak FA. Management of preterm labor: pharmacological and non-pharmacological aspects. Textbook of Perinatal Medicine. 2nd Edition. Cap. 130. UK, London: Informa Healthcare; 2006. pp 1394–1400.
   Google Scholar
• Nakamura O. Children’s immunology, what can we learn from animal studies (1): Decidual cells induce specific immune system of feto-maternal interface. J Toxicol Sci 2009;34 Suppl 2:SP331–SP339.
   PubMedGoogle Scholar
• Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009;80:91–99.
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J. Progesterone-mediated immunomodulation in pregnancy: its relevance to leukocyte immunotherapy of recurrent miscarriage. Immunotherapy 2009;1:873–882.
   PubMed Web of Science ®Google Scholar
• Raghupathy R. Manipulation of cytokine production profiles as a therapeutic approach for immunologic pregnancy loss. Indian J Biochem Biophys 2008;45:229–236.
   PubMed Web of Science ®Google Scholar
• Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 2005;97:389–396.
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Par G, Dombay G, Smart YC, Volgyi Z. The antiabortive effect of progesterone-induced blocking factor in mice is manifested by modulating NK activity. Cell Immunol 1997;177:194–199.
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol 2002;21:471–495.
   PubMedGoogle Scholar
• Daya S. Luteal support: progestogens for pregnancy protection. Maturitas 2009;65 Suppl 1:S29–S34.
   Google Scholar
• Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions. Best Pract Res Clin Obstet Gynaecol 2008;22:375–389.
   PubMed Web of Science ®Google Scholar
• Liu J, Matsuo H, Laoag-Fernandez JB, Xu Q, Maruo T. The effects of progesterone on apoptosis in the human trophoblast-derived HTR-8/SV neo cells. Mol Hum Reprod 2007;13:869–874.
   PubMed Web of Science ®Google Scholar
• Devoto L, Kohen P, Muñoz A, Strauss JF 3rd. Human corpus luteum physiology and the luteal-phase dysfunction associated with ovarian stimulation. Reprod Biomed Online 2009;18 Suppl 2:19–24.
   PubMed Web of Science ®Google Scholar
• Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, Garfield RE. Progesterone, but not 17-α-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008;199:391.e1–391.e7.
   Web of Science ®Google Scholar
• Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;CD003511.
   Google Scholar
• Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. BMJ 2004;329:152–155.
   PubMed Web of Science ®Google Scholar
• Kalinka J, Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 2005;53:166–171.
   PubMed Web of Science ®Google Scholar
• Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007;87:613–618.
   PubMed Web of Science ®Google Scholar
• Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265–274.
   PubMedGoogle Scholar
• Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96:275–280.
   PubMedGoogle Scholar
• Walch K, Hefler L, Nagele F. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial. J Matern Fetal Neonatal Med 2005;18:265–269.
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 α-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–2385.
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Roura LC, Facchinetti F, Antsaklis A, Breborowicz G, Gratacos E, Husslein P, et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2011;24:659–667.
   PubMed Web of Science ®Google Scholar
• Ferre F, Uzan M, Janssens Y, Tanguy G, Jolivet A, Breuiller M, Sureau C, Cedard L. Oral administration of micronized natural progesterone in late human pregnancy. Effects on progesterone and estrogen concentrations in the plasma, placenta, and myometrium. Am J Obstet Gynecol 1984;148:26–34.
   PubMed Web of Science ®Google Scholar
• Noblot G, Audra P, Dargent D, Faguer B, Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203–209.
   PubMed Web of Science ®Google Scholar
• Baumbach J, Coonrod D, Shi SQ, Shi L, Balducci J, Garfield R. Inhibition of uterine contractility during pregnancy with various tocolytics alone or in combination with progesterone. Am J Obstet Gynecol 2011 (Abstract 26).
   Web of Science ®Google Scholar
• Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58–63.
   PubMed Web of Science ®Google Scholar
• da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–424.
   PubMed Web of Science ®Google Scholar
• Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011;283:423–429.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453.e1–4; discussion 421.
   PubMed Web of Science ®Google Scholar
• Istwan N, Rhea D, Desh C, Barton JR, Barton LA, Sibai B. 17 α-hydroxyprogesterone caproate in women with previous preterm delivery: does a previous term delivery influence effectiveness? Am J Obstet Gynecol 2011 (Abstract 27).
   Web of Science ®Google Scholar
• Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692–695.
   PubMed Web of Science ®Google Scholar
• Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011;38:272–280.
   PubMed Web of Science ®Google Scholar
• To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 2006;27:362–367.
   PubMed Web of Science ®Google Scholar
• DeFranco EA, O’Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697–705.
   PubMed Web of Science ®Google Scholar
• Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, Sheffield JS, et al.; Vaginal Ultrasound Trial Consortium. 17-α-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010;202:351.e1–351.e6.
   Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists (ACOG). Incidentally detected short cervical length. Committee Opinion No. 522. Obstet Gynecol 2012;119:879–882.
   PubMedGoogle Scholar
• Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462–469.
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, et al.; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31.
   PubMed Web of Science ®Google Scholar
• Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011;38:1–9.
   PubMed Web of Science ®Google Scholar
• Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, Da Fonseca E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1–124.19.
   PubMed Web of Science ®Google Scholar
• O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687–696.
   PubMed Web of Science ®Google Scholar
• Christian MS, Brent RL, Calda P. Embryo-fetal toxicity signals for 17α-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med 2007;20:89–112.
   PubMed Web of Science ®Google Scholar
• Calda P. Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth. J Matern Fetal Neonatal Med 2009;22:540–542.
   PubMed Web of Science ®Google Scholar
• How HY, Sibai BM. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther Clin Risk Manag 2009;5:55–64.
   PubMedGoogle Scholar
• Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Saltzman DH. Increased incidence of gestational diabetes in women receiving prophylactic 17α-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007;30:2277–2280.
   PubMed Web of Science ®Google Scholar
• O’Brien JM. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should. Am J Obstet Gynecol 2011;204:e16–7; author reply e17.
   Web of Science ®Google Scholar
• Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, et al.; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Follow-up of children exposed in utero to 17 α-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865–872.
   PubMed Web of Science ®Google Scholar
• Combs CA, Maruel K, Garite T, Porto M. 17-hydroprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. Am J Obstet Gynecol 2011 (Abstract 11).
   Web of Science ®Google Scholar
• O’Brien JM, Lewis DF. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. J Reprod Med 2009;54:73–87.
   PubMed Web of Science ®Google Scholar
• Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA, Romero R. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010;202:548.e1–8.
   PubMed Web of Science ®Google Scholar
• Werner EF, Han CS, Pettker CM, Buhimschi CS, Copel JA, Funai EF, Thung SF. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol 2011;38:32–37.
   PubMed Web of Science ®Google Scholar
• Berghella V. Society for Maternal–Fetal Medicine (SMFM). Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. SMFM clinical guideline. Am J Obstet Gynecol 2012 (In Press).
   Web of Science ®Google Scholar
• Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 α-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–461.
   PubMed Web of Science ®Google Scholar
• Combs CA, Garite T, Maurel K, Das A, Porto M; Obstetrix Collaborative Research Network. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2010;203:248.e1–248.e9.
   Web of Science ®Google Scholar